8-K Announcements
6Material company update
May 6, 2026·SEC
Material company update
Apr 10, 2026·SEC
Material company update
Mar 4, 2026·SEC
Vir Biotechnology, Inc.(VIR)Earnings, Financials & Key Ratios
VIR•NASDAQ
$10.19
Price updated Jun 30, 2026
AboutVir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.Show more
- Revenue$69M-7.6%
- EBITDA-$456M+20.3%
- Net Income-$438M+16.1%
- EPS (Diluted)-3.16+17.5%
- Gross Margin82.92%+115.2%
- EBITDA Margin-665.65%+13.7%
- Operating Margin-682.68%+13.7%
- Net Margin-638.87%+9.2%
- ROE-45.73%-20.0%
VIR Price & Volume
Vir Biotechnology, Inc. (VIR) stock price & volume — 10-year historical chart
Loading chart...
Persistent Clinical Burn Challenges Long-term Solvency
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Clinical binary execution risk
Key Thesis Takeaways
- Vir Biotechnology faces a precarious transition as it pivots from pandemic-era revenue to a high-cost, R&D-intensive clinical pipeline.
- The company's inability to scale operating expenses, which frequently exceed $100 million per quarter, suggests a reliance on milestone-driven inflows that remain inherently unpredictable.
- Investors should monitor the rapid erosion of the asset base, which has contracted from $1.9 billion in 2023Q4 to $1.0 billion in 2026Q1, as the current cash burn trajectory may necessitate dilutive external financing.
Verdict Logic
the company's inability to generate positive free cash flow, evidenced by a 2026Q1 free cash flow of -$132.8 million, indicates a high risk of liquidity depletion without a major strategic pivot.
VIR Growth Metrics
Vir Biotechnology, Inc. (VIR) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years0.39%
3 Years-65.12%
TTM213.96%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM23.36%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM25.83%
Return on Capital
10 Years-26.52%
5 Years-7.65%
3 Years-38.51%
Last Year-42.76%
VIR Recent Earnings
Vir Biotechnology, Inc. (VIR) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 4/12 qtrs (33%)●Beat Revenue 4/12 qtrs (33%)
Q2 2026Latest
May 6, 2026Metric
Actual
Est
EPS
$0.85-8400.0%
$0.01
Rev
$29,000-100.1%
$55M
Q1 2026
Feb 23, 2026Metric
Actual
Est
EPS
$0.31+26.2%
$0.42
Rev
$64M+221.9%
$20M
Q4 2025
Nov 5, 2025Metric
Actual
Est
EPS
$1.17-67.1%
$0.70
Rev
$240,000-98.8%
$20M
Q3 2025
Aug 6, 2025Metric
Actual
Est
EPS
$0.80-11.1%
$0.72
Rev
$1M-55.4%
$3M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 6, 2026 | $0.85vs $0.01-8400.0% | $29,000vs $55M-100.1% |
| Q1 2026 | Feb 23, 2026 | $0.31vs $0.42+26.2% | $64Mvs $20M+221.9% |
| Q4 2025 | Nov 5, 2025 | $1.17vs $0.70-67.1% | $240,000vs $20M-98.8% |
| Q3 2025 | Aug 6, 2025 | $0.80vs $0.72-11.1% | $1Mvs $3M-55.4% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Vir Biotechnology, Inc. (VIR)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $10.19 | $1.64B | -3.22 | -7.61% | -638.87% | -45.73% | — | |
| $623.54 | $64.79B | 15.03 | 0.99% | 29.65% | 14.32% | — | |
| $4.26 | $1.32B | 213.00 | 22.23% | -6.63% | — | — | |
| $3.06 | $127.43M | -900.00 | 10.37% | 52.16% | — | — | |
| $8.37 | $1.94B | 13.95 | 19.63% | 32.43% | 38.97% | — | |
| $3.64 | $261.08M | 11.03 | -31.8% | 21.61% | 10.62% | — |
Compare VIR vs Peers
Vir Biotechnology, Inc. (VIR) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
VIR SEC Filings & Documents
Vir Biotechnology, Inc. (VIR) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when VIR posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
VIR Frequently Asked Questions
Vir Biotechnology, Inc. (VIR) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Vir Biotechnology, Inc.'s revenue?
Vir Biotechnology, Inc. (VIR) reported $65.5M in revenue for fiscal year 2025. This represents a 43856% increase from $0.1M in 2017.
How fast is Vir Biotechnology, Inc. growing?
Vir Biotechnology, Inc. (VIR) saw revenue decline by 7.6% over the past year.
Is VIR profitable?
Vir Biotechnology, Inc. (VIR) reported a net loss of $442.7M for fiscal year 2025.
Dividend & Returns
What is VIR's return on equity?
Vir Biotechnology, Inc. (VIR) has a return on equity (ROE) of -45.7%. Negative ROE indicates the company is unprofitable.
What is Vir Biotechnology, Inc.'s free cash flow?
Vir Biotechnology, Inc. (VIR) had negative free cash flow of $444.8M in fiscal year 2025, likely due to heavy capital investments.